DHR
Danaher Corporation
$224.43
-2.01% 2026-10-19
Health CareS&P 500
DHRSPY
1W
+1.5%
1M
+6.1%
3M
+11.8%
6M
+15.2%
YTD
-1.4%
1Y
+8.1%
Grades vs sector
Momentum35th pct in sectorC-
Momentum
35th pct in sector
12-1 return: +3.6%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Growth32nd pct in sectorD+
Growth
32nd pct in sector
Revenue growth (YoY): +5.5%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Value27th pct in sectorD+
Value
27th pct in sector
Forward E/P: 4.1% · EBITDA/EV: 4.4%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Profitability58th pct in sectorB-
Profitability
58th pct in sector
Profit margin: +15.9% · Return on equity: +7.6%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Revisionsno data–
Revisions
no data
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 3 live models right now.
Momentum Top 15
rank 268 of 499 · 12-1 momentum % 8.3
Quality Growthnot ranked (outside this model's universe or screens)
Momentum Blendnot in the current book
Key stats
Market cap$157.8B
P/E (trailing)40.0
P/E (forward)24.1
52-week range160.93 – 242.80
Revenue growth (YoY, latest qtr)+5.5%
Dividend yield0.70%
Analyst consensusStrong Buy (22)
Mean price target$244.14 (+9%)
Valuation & fundamentals
Bottom line
Looks expensive
Model read-out from the numbers below, not advice. Score -3 (DCF counts double).
▼DCF (base case)below the price by 56%
▼Forward P/E vs sector24.1x vs median 17.6x
•Piotroski F-score5/9
▲Altman Z12.5 (safe)
•Net debt / EBITDA3.0x
•Analyst target+9% (22 analysts)
Discounted cash flow
Bear
$49
-78%
growth -4% · disc. 9.2% · term. 2.0%
Base
$100
-56%
growth 1% · disc. 8.2% · term. 2.5%
Bull
$175
-22%
growth 4% · disc. 7.2% · term. 3.0%
A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.
Reverse DCFfor context, not a signal
A normal DCF guesses future cash flows and works out a price. A reverse DCF runs it backwards: it starts from today's price and asks how fast free cash flow would have to grow to justify it. It tells you what the market is assuming, not whether the stock is cheap or expensive, and it is not a buy or sell signal. Glossary
Today's price assumes free cash flow grows about 10% a year for 10 years.
Implied
+10%/yr
FCF, last 3 yrs
-11%/yr
FCF, last 5 yrs
-1%/yr
Revenue, last 3 yrs
-3%/yr
Revenue, last 5 yrs
+2%/yr
Same inputs as the DCF above: trailing free cash flow 5.5B, 8.2% discount rate, 2.5% growth after year 10, net debt and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.
Edit assumptions · recalculates instantly
Your value per share–
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-26). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.80 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs Health Care
P/E (trailing)
pricier
sector median 29.9× · 72nd pct
40.0×pricier
Forward P/E
pricier
sector median 17.6× · 70th pct
24.1×pricier
EV / EBITDA
pricier
sector median 15.8× · 79th pct
24.6×pricier
Price / sales
pricier
sector median 3.1× · 73rd pct
6.3×pricier
Price / book
cheaper
sector median 3.5× · 43rd pct
3.0×cheaper
FCF yield
pricier
sector median 4.1% · 42nd pct
3.5%pricier
Forward EPS $9.30 vs trailing $5.61 (+66% expected growth). Forward P/E uses analysts' next-12-month estimate.
Backlog (remaining performance obligations)
RPO
$7.5B
as of 2026-06-26
vs a year ago
+53%
YoY
× TTM revenue
0.30×
coverage
Contracted revenue not yet recognized, from SEC filings (XBRL tag RevenueRemainingPerformanceObligation).
Quality & financial health
Gross margin
58.5%
Operating margin
20.4%
FCF margin
21.8%
Net margin
15.9%
Return on equity
7.6%
Return on invested capital
5.8%
Net debt / EBITDA
3.0×
Current ratio
1.7×
Interest cover
17.6×
Cash conversion (OCF/NI)
1.7×
Piotroski F-score 5/9 · last two fiscal years
✓ Positive net income✓ Positive operating cash flow✗ Return on assets improved✓ Cash flow above net income✗ Long-term debt / assets fell✓ Current ratio improved✓ No share dilution✗ Gross margin improved✗ Asset turnover improved
Altman Z-score 12.5 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Mean target
$244
+9%
Analysts
22
Strong Buy
Range
$200–$310
low – high
● price · ◆ mean target
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $24.6B | $3.6B | $5.3B |
| 2024 | $23.9B | $3.9B | $5.3B |
| 2023 | $23.9B | $4.8B | $5.8B |
| 2022 | $26.6B | $7.2B | $7.4B |
| 2021 | $24.8B | $6.4B | $7.1B |
| 2020 | $22.3B | $3.6B | $5.4B |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR -2.7%.
Earnings
Next report: 2026-10-21 · before open · EPS est 1.92
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-07-21 | 1.84 | 1.94 | +5.3% |
| 2026-04-21 | 1.94 | 2.06 | +6.5% |
| 2026-01-28 | 2.19 | 2.23 | +2.0% |
| 2025-10-21 | 1.72 | 1.89 | +9.8% |
| 2025-07-22 | 1.64 | 1.80 | +9.5% |
| 2025-04-22 | 1.64 | 1.88 | +14.4% |
| 2025-01-29 | 2.16 | 2.14 | -1.1% |
| 2024-10-22 | 1.57 | 1.71 | +8.9% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $6.3B | +5.5% |
| 2026-03-31 | $6.0B | – |
| 2025-12-31 | $6.8B | – |
| 2025-09-30 | $6.1B | – |
| 2025-06-30 | $5.9B | – |
Analyst actions
Morgan Stanley
PT $240
2026-10-13 · main
Overweight → OverweightPT $240
TD Cowen
PT $255
2026-10-13 · main
Buy → BuyPT $255
Barclays
PT $255
2026-10-07 · main
Overweight → OverweightPT $255
RBC Capital
PT $250
2026-10-05 · main
Outperform → OutperformPT $250
Guggenheim
PT $250
2026-10-01 · main
Buy → BuyPT $250
Wells Fargo
PT $195
2026-07-22 · main
Equal-Weight → Equal-WeightPT $195
Recent dividends
2026-09-30: $0.400 · 2026-06-26: $0.400 · 2026-03-27: $0.400 · 2025-12-26: $0.320 · 2025-09-26: $0.320 · 2025-06-27: $0.320 · 2025-03-28: $0.320 · 2024-12-27: $0.270
Insider trades
Blair Rainer
$2.5M
Director, President & CEO · 2026-08-21
SELL$2.5M
Blair Rainer
$8.6M
Director, President & CEO · 2026-08-21
SELL$8.6M
Blair Rainer
$1.7M
Director, President & CEO · 2026-08-21
SELL$1.7M
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
News
8 Stocks That Are Much Riskier Plays Than They Look
Barrons.com · 8h ago
Roper Technologies (ROP) vs. Danaher (DHR): Which Is the Better Long-Term Capital Allocator?
Insider Monkey · Oct 18
Global Proteomic Biomarker Analytics Market: Five-Year Forecast by Application, Technology, Product, and End User | Double-Digit Growth Boosts Cancer Diagnostics and Drug Discovery
GlobeNewswire · Oct 16
Stats refreshed 2026-10-19 19:03:01 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau
Coteau Systematic StrategiesSystematic equity research and model portfolios.Coteau Systematic Strategies publishes research, model portfolios and tools. It does not manage money or offer investment advice. Model results are hypothetical. Data: Yahoo Finance (delayed), SEC EDGAR.